Cargando…
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Topoisomerase I inhibitors are new compounds of interest for cancer chemotherapy. We performed a study with GI147211, a new semisynthetic camptothecin analogue, to determine the absolute bioavailability of the drug given orally. Patients with a histologically confirmed diagnosis of a solid tumour re...
Autores principales: | Gerrits, C. J., Schellens, J. H., Creemers, G. J., Wissel, P., Planting, A. S., Pritchard, J. F., DePee, S., de Boer-Dennert, M., Harteveld, M., Verweij, J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228077/ https://www.ncbi.nlm.nih.gov/pubmed/9328158 |
Ejemplares similares
-
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
por: Gerrits, C. J., et al.
Publicado: (1996) -
A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion.
por: Paz-Ares, L., et al.
Publicado: (1998) -
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996) -
Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development.
por: Gerrits, C. J., et al.
Publicado: (1997) -
Current sample handling methods for measurement of platinum-DNA adducts in leucocytes in man lead to discrepant results in DNA adduct levels and DNA repair.
por: Ma, J., et al.
Publicado: (1995)